Michael Kallelis serves as the Chief Executive Officer of Mikart, Inc., where he leverages his extensive background in growth strategies and operational excellence to drive the company’s mission as a leading Contract Development and Manufacturing Organization (CDMO). Under his leadership, Mikart has positioned itself as...
Michael Kallelis serves as the Chief Executive Officer of Mikart, Inc., where he leverages his extensive background in growth strategies and operational excellence to drive the company’s mission as a leading Contract Development and Manufacturing Organization (CDMO). Under his leadership, Mikart has positioned itself as a key player in the pharmaceutical landscape, specializing in Good Manufacturing Practice (GMP) for small-molecule drug development, formulation, and serialized packaging services. Michael’s expertise in oral solid dose and non-sterile liquids and suspensions has been instrumental in expanding Mikart's service offerings and enhancing its competitive edge.
With a proven track record in managing and motivating diverse teams, Michael excels at aligning organizational goals with market opportunities. His experience spans various sectors, from start-ups to Fortune 6 companies, allowing him to apply tailored growth strategies that resonate across different business environments. Notably, his involvement in Board of Directors, Initial Public Offerings (IPO), and mergers and acquisitions (M&A) has equipped him with a robust understanding of the complexities involved in scaling operations and navigating the regulatory landscape of drug development.
Key projects under Michael's stewardship include the successful commercialization of innovative drug formulations and the implementation of advanced technology transfer processes that streamline production efficiency. His commitment to fostering a culture of collaboration and continuous improvement has not only enhanced Mikart’s operational capabilities but also solidified its reputation as a trusted partner in the pharmaceutical industry. With a focus on clinical development and a deep understanding of the nuances of the drug development lifecycle, Michael Kallelis is dedicated to driving Mikart's growth while maintaining the highest standards of quality and compliance.
